stockrowCardio Diagnostics Holdings, Inc.
CDIO Healthcare Biotechnology
Cardio Diagnostics Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14,800.00, down 57.6% from fiscal 2024.
- Revenue
- +23.8%
- EPS
- +47.4%
- Free cash flow
- +2.59%
Quarter to September 2026, against a year earlier
Follow CDIO
Alert me
Cardio Diagnostics Holdings, Inc. (CDIO) EV/Sales
As of 6 November 2026, Cardio Diagnostics Holdings, Inc. (CDIO) trades at a EV/Sales of 61.5×. Over the past ten years it has ranged from −220× (February 2026) to 985× (December 2024); the current reading is higher than 73% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | −24.5× | — |
| FY2024 | 812× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 110× | 79.34% |
| Jun 2026 | 61.3× | — |
| Mar 2026 | −92.1× | — |
| Dec 2025 | −24.5× | — |
| 10 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| CANF Can-Fite Biopharma Ltd compare | −8.7× |
| SNTI Senti Biosciences, Inc. compare | −1.1× |
| RVPH Reviva Pharmaceuticals Holdings, Inc. compare | n/m |
| PULM Pulmatrix, Inc. compare | 0.8× |
| NIKI Niki BioSolutions, Inc. compare | 1.3× |
| CNSY Cerenome, Inc. compare | 1.5× |
| IMNN Imunon, Inc. compare | 6.2× |
| PCSA Heatwurx Inc. compare | 49.5× |
| CDIO Cardio Diagnostics Holdings, Inc. | 61.5× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)